Bengaluru, Nov. 16 -- Synopsis: A USD 95 billion weight loss revolution is reshaping the global healthcare landscape, and India is emerging as one of its fastest-growing frontiers. As GLP-1 drugs race toward mass adoption and patent expiries open the door for generics, some Indian companies are quietly preparing for a big opportunity.

The global market for GLP-1-based weight loss drugs is set for explosive growth, expected to rise from USD 13.84 billion in 2024 to USD 48.84 billion by 2030, reflecting a CAGR of 18.5 percent, according to Grand View Research.

Goldman Sachs also projects the anti-obesity drug market could reach as high as USD 95 billion by 2030, making it one of the fastest growing healthcare segments globally.

India's g...